Tuesday, July 08, 2008

Boy cuts off locks for good cause

Boy cuts off locks for good cause
Clarksville Leaf Chronicle - Clarksville,TN,USA
Tidwell likes to watch the show in part because Montel Williams, like her, has multiple sclerosis. “A little girl came out who had no hair, because she had ...
See all stories on this topic
Health column: Living with multiple sclerosis
Daily News Transcript - Norwood,MA,USA
There are four main subtypes of multiple sclerosis: relapsing remitting MS, secondary progressive MS, primary progressive MS, and progressive relapsing MS. ...
See all stories on this topic

Out of the Gate: Teva drops on Copaxone results
CNNMoney.com - USA
PLC's Tysabri. Mylan Inc. has the rights to sell a generic form of Copaxone in the US, major markets in Europe and elsewhere. Teva is also developing other ...
See all stories on this topic


Teva investors in hysteria
Globes - Rishon Le-Zion,Israel
Cohen notes that Teva also has an oral drug for multiple sclerosis, Laquinimod, which is being jointly developed with Active Biotech AB (OMX: ACTI). ...
See all stories on this topic
Teva says higher dose of multiple sclerosis drug shows no ...
RTT News - Williamsville,NY,USA
Multiple Sclerosis, or MS, a progressive, demyelinating disease of the central nervous system, affecting the brain, spinal cord and optic nerves, ...
See all stories on this topic

Copaxone (40mg dose) (Teva)

Ahead of the Bell: Teva shares edge up
Forbes - NY,USA
Teva shares sank 8.5 percent Monday after the company said tests showed a 40-mg dose of Copaxone was no more effective than the original 20-mg version. ...
See all stories on this topic

Health Winners & Losers: Teva
TheStreet.com - USA
Teva TEVA skidded after the company said that according to top-line results of a trial dubbed "FORTE" the higher, 40mg dose of Copaxone was no more ...
See all stories on this topic

ADRs in Focus: Israel index dips after Teva report
Forbes - NY,USA
Teva said Monday that data from a late-stage study on the drug Copaxone showed that a 40-mg dose of the drug is no more effective than a 20-mg dose. Teva's ...
See all stories on this topic

Mon: Teva drops on Copaxone results
Globes - Rishon Le-Zion,Israel
... TASE: TEVA) was the focus of attention following the failure of the trial of the Copaxone 40 mg dosage, which was shown to be no more effective than the ...
See all stories on this topic

Movers: Marshall & Ilsley, UBS, Anheuser-Busch
BusinessWeek - USA
Teva Pharmaceutical Industries (TEVA) says top-line results from Phase III study designed to assess efficacy, safety and tolerability of glatiramer acetate ...
See all stories on this topic

Option Update: Teva Pharmaceutical volatility flat; shares sell off
BloggingStocks - USA
... 40mg dose of its multiple sclerosis drug Copaxone was not more effective in reducing the relapse rate than the 20mg dose already approved. TEVA overall ...
See all stories on this topic


Opexa’s Phase IIb Study of Tovaxin® Receives Positive Review from ...
Business Wire (press release) - San Francisco,CA,USA
Recently announced two-year follow up data from Phase I/II clinical studies of 22 patients showed 73% of patients on Tovaxin remained relapse free after two ...
See all stories on this topic

Opexa Therapeutics Says Data Safety Monitory Board Recommends To ...
RTT News - Williamsville,NY,USA
The primary endpoint of the Phase IIb trail is the cumulative number of contrast enhancing brain lesions using MRI, an important and objective measure of MS ...
See all stories on this topic

Market Report -- In Play (OPXA)
MSN Money - USA
Opexa's Phase IIb Study of Tovaxin receives 'positive' review from Data Safety Monitoring Board Co announces that the Data Safety Monitoring Board ...
See all stories on this topic

OPXA: Data Safety Monitoring Board Recommends Continuation of Ph ...
Trading Markets (press release) - Los Angeles,CA,USA
Opexa Therapeutics, Inc. (OPXA) announced that the Data Safety Monitoring Board (DSMB) overseeing the on-going Phase IIb clinical study of Tovaxin has ...
See all stories on this topic

Raising awareness about spinal cord research
Canada.com - Don Mills,Ontario,Canada
The university research team, led by Dr. Michel Rathbone and Dr. Shucui Jiang, has successfully repaired injured spinal cords in laboratory rats using nerve ...
See all stories on this topic
McMaster part of new cancer study
Hamilton Spectator - Hamilton,ON,Canada
A new cancer research project involving McMaster University is setting out to develop more targeted treatment for the illness. The project, launched today, ...
See all stories on this topic


vitamin D

Who Needs More Vitamin D?
Washington Post - United States
The July 4 front-page article "Some Seek Guidelines to Reflect Vitamin D's Benefits" nicely summarized the risks of having too much or too little Vitamin D ...
See all stories on this topic

Vitamin D vanquishes reader's joint pain
Bradenton Herald - FL, United States
I have been struggling with joint pain and just found out that my vitamin D level is really low. My doctor put me on a megadose of 50000 IU (international ...
See all stories on this topic

Low vitamin D levels raise health risks for IBD patients
SmartBrief - Washington,DC,USA
Inflammatory bowel disease patients who do not have sufficient levels of vitamin D have lower bone mineral density, raising the risk of osteoporosis and ...
See all stories on this topic

Prenatal vitamin D linked to kids' dental health
Reuters - USA
By Megan Rauscher NEW YORK (Reuters Health) - By maintaining adequate vitamin D levels during pregnancy, mothers may be protecting their babies against ...
See all stories on this topic

Experts Urge Review Of Vitamin D Guidelines
Looking Fit - Phoenix,AZ,USA
The influx of research indicating that vitamin D may have a wide array of health benefits has intensified the debate over whether federal guidelines for the ...
See all stories on this topic

Is Vitamin D the Wonder Drug of the 21st Century?
eMaxHealth.com - Hickory,NC,USA
Reading the buzz in the press these days, one might think Vitamin D has a major role to play. A few months ago, I posted a story about vitamin D and breast ...
See all stories on this topic


FDA Requires Black-Box Warnings For Epilepsy Drugs
Enews 2.0 - London,England,UK
... products included in the FDA’s analysis are Pfizer Inc.’s Neurontin and Lyrica, Meda AB ’s Felbatol, UCB SA’s Keppra, sold by several drug manufacturers.
See all stories on this topic

FDA: Epilepsy Drugs Should Carry Suicidal Warning
eFluxMedia - USA
Additional drugs included in the FDA’s review are Pfizer’s Neurontin, Meda AB ’s Felbatol, UCB SA’s Keppra, Novartis AG’s Trileptal, Cephalon Inc.’s ...
See all stories on this topic

Epilepsy drugs may require strictest warning
Boston Globe - United States
Additional products included in the FDA's review are Pfizer Inc.'s Neurontin and Lyrica, Meda AB's Felbatol, UCB SA's Keppra, Novartis AG's Trileptal, ...
See all stories on this topic

0 Comments:

Post a Comment

Links to this post:

Create a Link

<< Home